在胃肠道恶性瘤中对抗HER2疗法的耐药性
Christiana Mo1,2, Michelle Sterpi1,2, Hyein Jeon1,2
1Department of Medical Oncology, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
Cancers
|August 29, 2024
概括
人类表皮生长因子2 (HER2) 驱动癌症的生长. 本综述探讨了HER2阳性胃肠道癌症,疗法和限制治疗有效性的抗药机制.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症研究 癌症研究
背景情况:
- 人类表皮生长因子2 (HER2) 是一个关键的受体氨酸激酶,与细胞生长和增殖有关.
- HER2过度表达/放大是各种恶性病的驱动因素,包括胃肠道癌症.
- 数十年来,向HER2一直是癌症研究的重点.
研究的目的:
- 审查目前的HER2表达模式和胃肠道恶性瘤的治疗策略.
- 分析 HER2 阳性癌症中耐药性的机制.
- 确定 HER2 向治疗中的挑战和未来方向.
主要方法:
- 关于HER2表达,疗法和抵抗机制的综合文献综述.
- 对基准临床试验数据的分析,包括ToGA试验.
- 综合有关胃食道,结肠直肠,胆道和小肠癌的信息.
主要成果:
- 阳性HER2的胃肠道恶性瘤呈现出不同的表达模式.
- 已建立的疗法显示出有效性,但通常受到获得的耐药性限制.
- 特定的耐药性机制,包括途径再激活和向突变,阻碍了治疗的有效性.
结论:
- 尽管取得了进展,但耐药性仍然是治疗HER2阳性胃肠道癌症的重要障碍.
- 了解抵抗机制对于开发更有效的治疗策略至关重要.
- 需要进一步的研究来克服耐药性并改善HER2驱动恶性瘤患者的治疗结果.
相关概念视频
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
154
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
154
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
181
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
181
Peptic Ulcer Disease IV: Management
78
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
78
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
335
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
335


